Genenta Science (NASDAQ:GNTA) Trading 2.4% Higher – What’s Next?

Genenta Science S.p.A. (NASDAQ:GNTA) rose 2.4% on Thursday . The stock traded as high as $5.30 and last traded at $5.30. Approximately 966 shares changed hands during trading, a decline of 90% from the average daily volume of 9,819 shares. The stock had previously closed at $5.18.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Genenta Science in a research note on Wednesday, October 2nd.

Genenta Science Price Performance

The firm’s fifty day moving average price is $5.22 and its 200-day moving average price is $4.30.

Institutional Investors Weigh In On Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. purchased a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science at the end of the most recent reporting period. 15.13% of the stock is owned by institutional investors.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.